RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. (Q47918793)
Jump to navigation
Jump to search
scientific article published on 7 August 2017
Language | Label | Description | Also known as |
---|---|---|---|
English | RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. |
scientific article published on 7 August 2017 |
Statements
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial (English)
M Lambiase
L Forgione
A Iannaccone
A Sacco
A M Rachiglio
E Martinelli
D Rizzi
S Pisconti
M Biglietto
R Bordonaro
T Troiani
T P Latiano
F Giuliani
S Leo
A Rinaldi
F Ciardiello
CAPRI-GOIM Investigators